{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-026790","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2026-08-10T20:35:21+00:00","discovered_at":"2026-08-10T20:37:00.452771+00:00","generated_at":"2026-08-10T20:37:20.348605+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DiaMedica Q2 loss $10.1M; PE trial shows 29.1 mmHg SBP drop","bullets":["Net loss $10.1M in Q2 2026 vs $7.7M Q2 2025; six-month loss $20.2M vs $15.4M.","Cash $43.5M at June 30, 2026 vs $59.9M at Dec 31, 2025; runway through 2027.","Phase 2 PE Part 1a: DM199 reduced SBP 29.1 mmHg (p<0.001) from 169.3 mmHg baseline; DBP 17.0 mmHg.","FGR Phase 2 first cohort of 6 patients (5 µg/kg) fully enrolled; topline results due September.","ReMEDy2 AIS trial enrollment >85% of 200 patients; interim analysis expected Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-026790","json":"https://secwatch.observer/filing/0001437749-26-026790.json","markdown":"https://secwatch.observer/filing/0001437749-26-026790.md","text":"https://secwatch.observer/filing/0001437749-26-026790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/0001437749-26-026790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/dmtp20260809_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:37:20.348605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}